Evan Rosenbaum

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

17h-index1.1kcitations169works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(84), Cancer Immunotherapy and Biomarkers(77), CAR-T cell therapy research(26), Lung Cancer Treatments and Mutations(20), Peptidase Inhibition and Analysis(17)

Publications169 total

Data from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in Sarcoma
Clinical Cancer Research·2026
Systemic Therapy Outcomes for Soft Tissue Leiomyosarcoma Patients in an Era of Next-Generation Sequencing
JCO oncology advances.·2026Open Access
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Cancer Research Communications·2025Open Access
Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
page 1 of 9Next →

Frequent Co-authors

William D. Tap(38), Sandra P. D’Angelo(34), Ping Chi(29), Ciara M. Kelly(29), Mrinal M. Gounder(28), Mark A. Dickson(28), Sujana Movva(24), Mary Louise Keohan(22), Li‐Xuan Qin(21), Benjamin A. Nacev(20), Cristina R. Antonescu(19), Jason E. Chan(17), Samuel Singer(17), Viswatej Avutu(16), Katherine A. Thornton(12), Sinchun Hwang(11), Joseph P. Erinjeri(10), Mark T.A. Donoghue(9), Emily K. Slotkin(8), Martee L. Hensley(7)